Cookie preferences

Essential storage keeps iPulse AI reliable. Optional analytics and LinkedIn ad measurement stay off unless you accept. Privacy Policy

Skip to main content

AI Investment Edge Podcast

Company research and market ideas, in conversation.

AI Investment Edge · from iPulse AI

EP 32 | AXA Stock Analysis: Is This Dividend Giant Ready to Soar?

Episode 3216:18 min

Research as of 27 Oct 2026

AXA stock analysis: can its dividend engine keep compounding when total profit grows more slowly than earnings per share? We examine the French insurer's claims, invested premiums, capital and cash returns, separating the headline yield from what the business can actually distrib

0:0016:18

In This Episode

AXA's dividend looks straightforward. Its cash is not. The French insurer can increase earnings per share even when total profit barely grows, while a large cash balance still comes with promises to policyholders. This episode asks whether AXA's insurance engine can support lasting shareholder returns.

Research checked 27 October 2026. The current evidence-weighted AI Consensus is Strong Buy at the one-year horizon and Buy at the five-year horizon, with the distinct immediate label Strong Buy & Keep for Dividends. Those ratings use the 26 October €42.33 close. The separate recording reference is the 27 October Euronext Paris €42.46 trade at 17:38 CET, also displayed as that day's valuation close.

Explore the AXA research

What AXA sells, and why the obligations matter

AXA provides motor, home, commercial property, liability, life, health and employee-protection insurance to households and businesses. AXA XL handles large commercial and specialty risks. Premiums compensate it for accepting defined risks; assets backing future claims can also generate investment income. That interval between collecting premiums and paying claims creates insurance float. It does not turn policyholders' money into unrestricted shareholder cash.

AXA sold AXA Investment Managers to BNP Paribas on 1 July 2025. It still invests the insurance assets on its balance sheet, but no longer owns that divested asset-management operation.

Four financial findings that change the investment argument

1. A larger slice does not always mean a larger business

H1 2026 underlying group earnings were €4.54 billion, up 2% on a reported basis. Underlying EPS rose 8% to €2.19 as diluted average shares fell about 6%. A smaller denominator helps explain why per-share growth exceeded total-profit growth. On a constant-currency basis, underlying earnings grew 4%, or 9% excluding AXA IM. These are different comparison bases.

The pizza analogy is useful: fewer slices can make each slice larger without enlarging the pizza. Buybacks can support EPS, but their value still depends on the repurchase price and the capital left for claims and growth. P&C earnings grew 6% and Life & Health earnings 11% at constant currency, providing evidence of underlying insurance improvement beyond share retirement.

2. A stable underwriting ratio can conceal opposing trends

The H1 P&C all-year combined ratio was 90.1%, versus 90.0%. Roughly, claims and expenses consumed 90 cents of each euro of insurance revenue before investment income and other items. This underwriting measure is different from a group net-profit margin.

  • Personal lines improved from 93.3% to 91.5%.
  • Commercial lines worsened from 89.9% to 90.9%.
  • Natural-catastrophe charges were 3.5 points, below the approximately 4.5-point normalized full-year budget.
  • Higher discounting of future claims benefited the reported ratio by about 0.2 point; that does not mean fewer physical claims occurred.

Retail repricing can offset commercial weakness, while a benign half-year weather bill can flatter the aggregate result. Actual H1 underlying ROE was 18.3%; the new plan's future 15–17% range describes another period.

3. Regulatory capital is not a spare cash account

Solvency II stood at 218% on 30 June: eligible regulatory capital was about 2.18 times the modeled requirement. The preceding year-end headline was 224%; a January debt-grandfathering transition reset the starting ratio to about 215%. The June ratio did not rise from 224%.

The September strategy deck identifies approximately €454 billion of general-account invested assets. These assets back obligations. Regulatory capital buffers the risks arising from invested assets and insurance obligations; the asset portfolio and the capital requirement are separate figures. Matching asset and liability maturities can reduce exposure, but credit losses, sovereign spreads and reserve errors remain important. Higher yields can improve future reinvestment income while a sudden spread shock weakens today's capital position.

4. Low physical spending does not mean low economic capital needs

H1 tangible and intangible purchases were €174 million. Insurance growth still consumes capital and reserves, while some technology spending runs through expenses. The new strategy targets retaining about 25% of underlying earnings, alongside 60% for dividends and 15% for annual buybacks.

AXA's AI ambition is €500–700 million of recurring annual pretax value by 2029, net of investment, across growth, underwriting and efficiency. It is a future target, not achieved savings or purely a headcount reduction. Amazon's data centers make investment visible as equipment; an insurer's binding investment constraint may instead be capital held against future promises.

Follow the cash from the subsidiaries to the parent

H1 operating cash flow fell to €7.96 billion from €15.39 billion. Larger operating-receivable/payable and other-asset/liability outflows explain much of the reduction, alongside contract and noncash reconciliation movements. Subtracting €174 million of physical and intangible purchases gives about €7.78 billion, but does not establish unrestricted owner free cash flow.

H1 2026 cash bridgeEUR billion
Opening net cash€20.97
Operating inflow+€7.96
Net investing outflow−€4.06
Financing outflow−€7.92
Currency effects+€0.97
Closing net cash€17.92

Figures are rounded. Dividends and share repurchases are financing uses, not operating expenses. Consolidated statutory cash flow and subsidiary-to-parent cash remittance answer different questions. Think of regulated subsidiaries as reservoirs: water in the system is not automatically available from the parent's tap.

Actual 2025 organic cash remittance was €7.5 billion. The new approximately €25 billion ambition is cumulative for 2027–2029, before holding costs and interest. It is neither annual free cash flow nor an automatic shareholder payout.

Valuation, fixed targets and dividend cash

The €42.46 reference is 11 times FY2025 underlying EPS of €3.86. This company alternative performance measure provides an illustrative price-to-underlying-earnings multiple, rather than a statutory trailing P/E or forward guarantee. FY2025 statutory net income of about €9.8 billion included the AXA IM disposal gain. Overlapping annual and interim periods must not be added together.

Fixed model endpointWeighted terminal price, EURCumulative price return from €42.46Assumed gross cash per shareGross cash-inclusive return
€48.54+14.32%€2.32+19.79%
€64.59+52.11%€11.60+79.43%

The last ordinary dividend was €2.32 per share, paid annually on 13 May 2026; that already-paid amount is excluded. Keeping future annual payouts flat at €2.32 illustrates one future May payment by the first endpoint and five by the later endpoint. These are assumptions, not five declared payments. Cash-inclusive returns add that cash once, before tax and fees, without reinvestment. The public rating uses a separate net-yield reinvestment method; its returns and these gross cash illustrations must not be substituted for one another.

The bullish mechanism, the ordinary frictions and both tails

  • Base and bull mechanism: disciplined insurance growth, gradual reinvestment of maturing bonds, adequate reserves and useful productivity can support earnings and distributions without requiring a permanently higher valuation multiple.
  • Ordinary frictions: softer commercial pricing, repair and medical inflation, recurring weather losses, and capital sensitivity to bond spreads. Annual policy renewals cannot instantly reprice every cost shock.
  • Distinct upside tail: capital generation and underwriting productivity exceed expectations enough to leave additional surplus for exceptional distributions, subject to capital needs and board decisions.
  • Distinct downside tail: major catastrophes coincide with a sovereign-credit or casualty-reserve shock, weakening both underwriting and invested assets. Remittances and discretionary buybacks could fall when shareholders expect cash returns.

The approximately 17-point Solvency II reform uplift expected in Q1 2027 was already disclosed in September, based on January conditions. It is not operating earnings or an announced special buyback. A genuinely favorable surprise would require more than receiving an expected regulatory effect.

The alpha-gap hypothesis is that investors overlook gradual per-share compounding in a dull European insurer. Bond rollover resembles a moving walkway: it can provide a continuing lift, while claims inflation pushes against it. The opposing case is that commercial softness, reserve uncertainty and sovereign risk justify the discount. A corrected cheap-P/E screen alone does not establish mispricing.

What the AI perspectives disagree about

The current released batch contains 14 contributions across nine frameworks and three model versions; 12 use the same Gemini version. These are correlated AI perspectives. The important disagreement is whether AXA needs a higher earnings multiple, or whether recurring earnings and dividends can carry the thesis at an ordinary insurer valuation. Optimistic reports that confuse disposal gains or broad cash aggregates with recurring owner earnings deserve less confidence than perspectives testing commercial and sovereign risk.

The current Strong Buy/Buy horizon labels are separate from September's original Buy/Buy labels, individual verdicts and the unlike all-advisor average.

The quarterly path and the next real test

The weighted path includes spring dips associated with modeled ex-dividend effects. Paying cash out can reduce the quoted price; ignoring the cash can understate shareholder return. Future model dates are analytical checkpoints, not announced ex-dividend dates or guaranteed corporate milestones. Dividend entitlement detaches on the ex-dividend date; cash is normally paid later. Other market movements can offset the all-else-equal adjustment in an actual traded price.

Fixed forecast quarterWeighted price, EURCumulative price return from €42.46
€45.72+7.68%
€47.46+11.77%
€47.04+10.79%
€48.54+14.32%
€49.66+16.95%
€51.45+21.17%
€51.07+20.27%
€52.47+23.57%
€53.58+26.18%
€55.41+30.49%
€55.08+29.72%
€56.54+33.17%
€57.76+36.03%
€59.57+40.30%
€59.15+39.30%
€60.43+42.31%
€61.68+45.27%
€63.50+49.54%
€63.17+48.77%
€64.59+52.11%

The next confirmed company event is the 29 October 2026 nine-month activity-indicator release. It remains future at the research cutoff and can test growth, pricing and capital; it is not a newly published full-year earnings report. The 15 September investor day has already occurred.

What changed since July, and what would change the view

July's research emphasized a post-restructuring cash harvest, unusually cheap screen multiples and buybacks. September's stronger perspectives challenged distorted valuation inputs and the softer commercial market. Actual new business evidence included the 31 July H1 release and the 15 September Growing Forward plan, raising the underlying EPS growth ambition from 6–8% to 7–9% for 2027–2029. Those are management targets. The AXA IM sale already belonged to July's story.

Our preceding stock episode was Adyen, Episode 31. Merchant settlement funds and insurance policy obligations have different legal and economic structures, but both demand care before calling every cash euro shareholder property.

  • Challenge the optimistic case if commercial rate cuts, claims severity or reserve strengthening weaken technical margins and remittances.
  • Watch whether new business consumes more capital than expected, while solvency takes priority over buybacks.
  • Give less credit to EPS growth driven mainly by a shrinking share count when recurring group profit stalls.
  • Challenge the pessimistic case if underwriting, recurring earnings and parent cash hold through a soft commercial cycle, supported by investment carry and useful productivity.

AXA's opportunity is disciplined compounding. Its dividend engine depends on underwriting and capital quality. The headline yield, cash balance and repurchase program are starting points for investigation, rather than substitutes for it.

Continue with three earlier conversations

Like, comment and subscribe. We are publishing a new podcast every day of the week except Thursday. Stay tuned for the next podcast on BNP Paribas.

Primary research conducted through the iPulse AI platform by Future Edge Group.

Primary evidence

Full episode notes and sources on Substack ↗

Full Transcript

Reviewed 27 Oct 2026 · Codex AI parent read all300selectedsegments, all1357segments across4whole takes and all328finaltoken-timedEnglishcaptioncues; primary and governed checks independent of upstreammanual/source-displayQA which remainsOPEN. Selected wholeV04noeditorialcuts/joins/padding/speedchanges; fullMP3/MP4decodes,6actual1080frames and3reduced320chartframes passed. No human/fulluninterruptedlistening/perfectauralclaim; phonetic/name/display and float-capital/insurance-premium/accounting compression/instruction-like phrase/event-scope limits retained in final-qa.json. Actual ordinaryRSS full decoded correlation0.9998463685382134 with zero lag establishes platform-transcode correspondence, not byteidentity or humanlistening. Select a timestamp to listen from that point. Download transcript

Full transcript · 30-second passages

  1. So how can a massive global insurer report rising earnings per share while its total overall profit barely grows at all? Yeah, it's a huge red flag if you aren't paying attention. Right. Welcome to AI Investment Edge, episode 32. If you're holding financial stocks or just looking for where the market is completely mispricing value, this is exactly the kind of puzzle you need to figure out. Because there's a core distinction you have to keep in mind, right? Profit is just an accrual-based accounting metric.

  2. Exactly. Whereas cash flow measures the actual cash movements. So just because an insurer's profit looks flat or maybe slightly rising, that doesn't mean their cash is doing the same thing. Right. Because sometimes, you know, rising earnings per share just reflects aggressive share repurchases. Which forces us to ask, what's the actual underlying quality of the remaining business? So today, we're going to synthesize 14 different AI-generated financial frameworks, analyst targets, and current market data for a deep dive into

  3. AXA. Before we really get into the mechanics of their earnings, I should establish the public evidence-weighted consensus. Yeah. Let's get that out of the way early. So checked October 27th on the October 26th close, 42.33 euros. The consensus is a strong buy at the one-year horizon and a buy at the five-year horizon. And for anyone tracking the platform research ratings, we need to be really clear. You have to keep the immediate strong buy and keep for dividends label entirely

  4. distinct from those horizon ratings. Oh, absolutely. I mean, those are platform research ratings, right? They're not mathematical promises of a soaring stock price. Yeah. And they're separate from individual opinions or like the all-advisor average. But let's frame up what you're actually buying with AXA. It's a France-based global insurer serving households and businesses. And when people hear insurance, they usually just think car crashes or house fires. Right. But we explicitly need to include life and health insurance.

  5. And employee protection cover is major parts of their business. That's alongside the motor, home, commercial property, and liability stuff. Yeah. Plus AXA XL, which handles the really large commercial and specialty risks. So structurally, they collect premiums to accept those risks. Right. And then the investment income they generate on the assets backing those promises, well, that supplies a completely distinct earnings stream from the underwriting itself. Which actually reminds me of our previous deep dive on Ping An. We talked about how you absolutely must examine an insurer's obligations, its

  6. investment returns, and the parent company's cash entirely separately. Yeah. You can't look at an insurer's balance sheet like it's a software company. Definitely not. Which brings up this idea of insurance float. You know, the premiums held before claims are paid. I feel like there's this big misconception that float is just free shareholder money. Oh, it is absolutely not free shareholder money. That float is highly regulated capital, strictly backing future liabilities. Right. And on the asset side, you should know AXA actually sold its asset management

  7. business, AXA IM, to BNP Paribas on July 1st, 2025. So they still invest their own insurance assets, but they don't own that fee management business anymore. Exactly. Okay. That sets the table perfectly. Now let's move straight from the business model into the mathematical reality of their performance. We have four key financial findings, starting with earnings. Yeah. This is where that initial puzzle comes from. So H1 group underlying profit was about 4.5 billion euros. Which is what, up only 2% on a reported basis?

  8. Right. Up 2% reported. Yet underlying earnings per share rose 8% to 2.19 euros. Because their diluted shares fell about 6%? Exactly. You know, we usually try to avoid the classic pizza analogy for share buybacks because it feels a bit basic. But here is actually the perfect warning. Yeah, it really is. Buybacks are literally dividing a pizza into fewer slices. You retire shares, so every remaining slice, the EPS, is mathematically larger. But they haven't actually baked a larger pizza.

  9. Right. The organic growth of the profit pool hasn't suddenly exploded by 8%. That's just denominator shrinkage. And EPS growth alone does not measure organic business growth. Definitely not. Plus, you have to look at the different bases they use. Like, on a constant currency basis, underlying earnings rose 4%. Or, if you exclude the sold AXA IM business completely, it rose 9%. Wow. Okay. So those are three completely different bases, not just three ways of describing

  10. the same growth rate. Exactly. You have to read the reports carefully. So let's connect that modest 2% profit growth to our second finding, which is profitability. How much are they actually making on the insurance side? Well, in H1, the property and casualty all year combined ratio was 90.1% compared to 90.0% last year. Okay. Meaning for every euro of premium they take in, they pay out about 90 cents in claims and expenses. Yeah, but an aggregate number that flat usually hides some internal friction.

  11. Always does. But it's underneath it. Personal lines actually improved, dropping from 93.3% to 91.5%. But commercial lines worsened from 89.9% up to 90.9%. Okay. But how do interest rates factor into that ratio? That's the crucial implication here. Higher interest rates increase the discounting of future claims, which mathematically improved the reported ratio by 0.2 points. I want to pause on that mechanism because it's vital.

  12. Discounting future claims improves the reported ratio on paper because of the time value of money, right? Yes. Higher rates mean the cash they hold today will grow more by the time they pay out. Right. It's an underwriting measure. Exactly. It does not mean the physical claims like the car crashes suddenly vanished. Exactly. And while strong retail pricing offsets the commercial weakness right now, one benign half year doesn't prove permanent pricing power. Fair point. Which brings us to the third finding, the balance sheet.

  13. Right. Solvency II was 218% at June 30. That's their capital versus the model requirement. And keep in mind, a January transition reset their starting ratio to 215%. So that capital buffers their underwriting and investment risks. But the 454 billion euro invested asset portfolio, that's a completely separate figure, right? Entirely separate, yeah. So if they're sitting at 218%, they clearly have excess capital over the minimum. But does that mean they can just, you know, sweep all that cash into a special

  14. dividend? No, absolutely not. Excess capital over the minimum is not automatically distributable. Assets and liabilities are managed together. Right. So think about a sovereign credit shock. If government bond spreads widen, the value of the bonds AXA holds drops. That hurts their capital position today. Even though those higher yields will improve future reinvestment down the line. Exactly. The same force has opposite effects on today's asset values and tomorrow's coupons. Which leads us perfectly into the fourth finding, investment and the spoken cash

  15. bridge. Let's look at their tech investments. Well, H1 physical and intangible purchases were only 174 million euros. But AI is projected to generate 500 to 700 million euros of recurring pre-tax value by 2029. And that's net of investment across growth and efficiency. It's not just banked savings. Right. But that low 174 million figure for physical purchases trips people up. Yeah. I mean, compare it to our deep dive on Amazon.

  16. Amazon's investment constraint is visible. You can literally drive past a massive data center. But an insurer's constraint is regulatory capital. It is. Which is why we need to clearly map out the cash bridge. Let me speak the exact math here. Let's hear it. So H1 operating inflow was about 8 billion euros down from about 15 billion last year. Mostly due to larger receivable, payable and other balance movements. Okay. 8 billion operating. Right. About 8 billion operating minus 4 billion investing minus 8

  17. billion financing plus 1 billion currency. That means cash falls from about 21 billion down to 18 billion. That's a perfect illustration that cash flow from operations minus small capex is not unrestricted shareholder free cash flow. Not at all. It's like regulated reservoirs. The regulated subsidiaries are separate reservoirs. Just because there's water in a regional reservoir doesn't mean it's automatically

  18. at the parent company's tap in Paris. Yes. Consolidated cash and subsidiary remittance are totally different things. So that 25 billion euro cumulative 2027 to 2029 upstream target, that's before holding costs and interest. It's not an annual free cash flow and definitely not a promised payout. Exactly. So how does all this translate to valuation? If we use that separately dated October 27th 42.46 euro Euronext trade, that's roughly 11 times their actual reported FY 2025 underlying EPS of 3.86

  19. euros. Right. A completed historical year. But FY 2025 net income was 9.8 billion euros and that included the AXA IM sale gain. Oh, so you can't count that as recurring. No, don't count it as recurring. Got it. Let's look at the fixed base, the bull, the bear, and the dividend cash based on that 42.46 euro trade. What are the targets? Well, the fixed targets for the third quarter of 2027 are about 49 euros.

  20. For the third quarter of 2031, it's about 65 euros. So that's cumulative price returns of about 14% and 52%? Yeah. But you have to factor in the dividend cash. The annual ordinary dividend is about 2.3 euros, excluding the already paid May 2026 one. Right. Assuming flat future May payments. One payment by 2027 gives about 2.3 euros gross cash. And five payments by 2031 gives about 11.6 euros gross cash.

  21. Which yields about 19.8% and just under 80% cumulative cash inclusive returns. That's before tax and fees. No reinvestment assumed. Right. And just clarify, the public net yield reinvestment rating differs from that. Okay. So what pushes this into a bull or bear scenario? Well, first, strictly define investment carry as income after relevant funding or guarantee costs. It's separate from underwriting. Okay. The bull case is profitable growth, useful carry, compounding without multiple

  22. expansion. The bear case is commercial softness, reserve strengthening, and investment losses. And to be clear, there are no invented, synthesized bull or bear endpoints or probabilities here. And absolutely no guaranteed buyback floors. No. None. Let's talk about the four quadrants with those upside and downside tails. What's normal? Normal quadrants are renewing low coupon bonds at higher yields, resilient retail demand versus soft commercial pricing, expensive repairs, and capital sensitivity

  23. to bond spreads. It's basically a moving walkway analogy, right? The gradual bond rollover gives you this continuing lift as old bonds mature into higher yields. But claims inflation is moving against you. That's a great way to picture it. So what's the upside tail? Stronger capital generation plus AI underwriting. But a vital correction here. The expected 17-point Solvency II uplift in Q1-2027 is already disclosed based on January conditions. So it's not new earnings or some announced special buyback windfall.

  24. Right. It's already known. As for the downside tail, that would be a cluster of catastrophes hitting alongside a sovereign credit or casualty reserve shock. Wait, let me push back a bit. AXA is huge. They have a 218% solvency ratio. Doesn't that scale essentially put a floor on the stock price? No, it firmly does not. Neither scale nor that ratio creates a price floor. Under severe stress, a buyback pause or a dividend cut is definitely possible.

  25. Right, because parent dividends depend on liquidity, costs, and board decisions to protect solvency. Exactly. Which brings us to the alpha gap. The hypothesis is that investors overlook this steady per-share compounding because, you know, European insurance looks dull. Right, but the counter-argument is that the discount might correctly price in that commercial softness and sovereign risk. And this is where the advisor disagreement comes in. We should explicitly state that all 14 contributions are AI-generated.

  26. Yes. They span nine frameworks and three model versions, with 12 using the same Gemini version, showing correlated AI perspectives. So what's the core disagreement between the AI frameworks? It's about whether AXA needs multiple expansion or if earnings and dividend compounding is enough. Why do they disagree? Some of the overly optimistic models mistook the sale gains for recurring earnings. The stronger forensic AI models corrected this. Ah, which is why the current ratings remain distinct from the original September Buy

  27. Buy labels. Exactly. Let's map out the quarterly path. The 20-quarter path rises to about 46 euros in Q4 2026 and about 47 euros in Q1 2027. But investors have to watch for modeled spring ex-dividend dips. Explain that mechanism. Sure. All else equal, the price reference adjusts down when the dividend entitlement detaches. The cash is paid later. And of course, actual market trades can move differently. Right. And as for actual events, the September 15th investor day already happened.

  28. The October 29 indicators remain in the future. And those only test premiums, not full year earnings. Yeah. And note that we use event local time only. No production Dubai conversions. So how did the thesis change from July to September? Well, July emphasized the cash harvest and cheap multiples. But September challenged the distorted valuations and soft commercial markets. And there was an actual strategy change on September 15th, right?

  29. AXA raised their underlying EPS growth ambitions from 6% to 8% to 7% to 9% for 2027 to 2029. Yes, though those are targets, not achieved growth. And the AXA IM sale closing in July 2025 was already in July's story. Which brings up our last public stock baseline, Adyen from episode 31. Oh, that's a good comparison. Yeah. I mean, Adyen's merchant settlement money and an insurer's policy obligations are very different. But both warn you against treating every reported cash euro as shareholder property.

  30. Perfectly said. So how does this thesis get invalidated? The bear challenge is if commercial rate cuts outpace claims trends or casualty reserves need strengthening or cash remittances disappoint while the board protects solvency. Right. Because rising EPS driven mainly by a shrinking denominator like the buybacks is way less persuasive if group profit stagnates. But on the flip side, the bull challenge is that the pessimistic case fails if

  31. technical margins and remittances hold through a soft cycle, while investment carry and AI productivity accrue. You really have to watch what is left after claims and capital retention. Okay, let's synthesize this. AXA could reward patient owners through recurring earnings in cash, but only if underwriting quality holds. We reiterate the strong buy 1Y and buy 5Y ratings. The opportunity is disciplined compounding, not a guaranteed launch.

  32. Exactly. We invite you to explore AXA's AI consensus, AI opinions, and profile and fundamentals on iPulse AI. Please like, comment, and subscribe. We are publishing a new podcast every day of the week except Thursday. Stay tuned for the next podcast on BNP Paribas. Oh, BNP Paribas. That connects right back to the AXA IM sale. It does. Actually, just a quick curiosity hook before we go. How exactly does BNP earn fees from that acquired asset management business?

  33. Basically, client assets under management, or AUM, are managed strictly for fees. Those are not automatically assets owned on BNP's balance sheet. So it's not bank-owned money. Always comes back to the regulated reservoirs, doesn't it? See you next time.